Short communication: A low-cost method for analyzing nevirapine levels in hair as a marker of adherence in resource-limited settings

AIDS Research and Human Retroviruses

Volumn 30, Issue 1, 2014, Pages 25-28

  Gandhi, Monica ^a   Yang, Qiyun ^a   Bacchetti, Peter ^a   Huang, Yong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG HAIR LEVEL; DRUG MONITORING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THIN LAYER CHROMATOGRAPHY; CHEMISTRY; HAIR; HIV INFECTIONS; PROCEDURES; PROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ANTI-HIV AGENTS; CHROMATOGRAPHY, THIN LAYER; HAIR; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; NEVIRAPINE; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 84891794014     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0239     Document Type: Article

References (21)

1. Berg KM and Arnsten JH: Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr 2006;43(Suppl 1):S79-S87.
2. Gandhi M and Greenblatt RM: Hair it is: The long and short of monitoring antiretroviral treatment. Ann Intern Med 2002;137(8):696-697.
3. Gandhi M, Ameli N, Bacchetti P, et al.: Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis 2011;52(10):1267-1275.
4. van Zyl GU, van Mens TE, McIlleron H, et al.: Low lopinavir plasma or hair concentrations explain second line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011;56(4):333-339.
5. Gandhi M, Ameli N, Bacchetti P, et al.: Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS 2009;23(4):471-478.
6. Gandhi M, Ameli N, Bacchetti P, et al.: Concentrations of Efavirenz in Hair Are Strongly Correlated with Virologic Response. 16th Conference on Retroviruses and Opportunistic Infections (CROI), Montreal, Canada, 2009; paper 692.
7. Gandhi M, Mwesigwa J, Aweeka F, et al.: Hair and plasma data show that lopinavir, ritonavir and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013;63(5): 578-584.
8. Beumer J, Bosman I, and Maes R: Hair as a biological specimen for therapeutic drug monitoring. Int J Clin Pract 2001;55:353-357.
9. Gandhi M, Greenblatt RM, Bacchetti P, et al.: A single nucleotide polymorphism in CYP2B6 leads to > 3-fold increases in efavirenz concentrations in intensive PK curves and hair samples in HIV-infected women. Journal of Infectious Diseases 2012;(9):1453-1461.
10. Nettles RE, Kieffer TL, Parsons T, et al.: Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis 2006;42(8):1189-1196.
11. Clevenbergh P, Garaffo R, Durant J, and Dellamonica P: PharmAdapt: A randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS 2002;16:2311-2315.
12. Wertheimer BZ, Freedberg KA,Walensky RP, Yazdanapah Y, and Losina E: Therapeutic drug monitoring in HIV treatment: A literature review. HIV Clin Trials 2006;7(2):59-69.
13. Cramer JA, Scheyer RD, and Mattson RH: Compliance declines between clinic visits. Arch Intern Med 1990;150(7): 1509-1510.
14. Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, and Hanna GJ: "White coat compliance" limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008;9(4):238-246.
15. World Health Organization: Consolidated guidelines on the use of ARV drugs for treating and preventing HIV infection. June 30, 2013. www.who.int/hiv/pub/guidelines/arv2013/short-summary/en/index.html.
16. Huang Y, Gandhi M, Greenblatt RM, Gee W, Lin ET, and Messenkoff N: Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir, and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom 2008;22(21):3401-3409.
17. Huang Y, Yang Q, Yoon K, et al.: Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2011;401(6):1923- 1933.
18. Shewiyo DH, Kaale E, Ugullum C, et al.: Development and validation of a normal-phase HPTLC method for the simultaneous analysis of lamivudine, stavudine, and nevirapine in fixed-dose combination tablets. J Pharm Biomed Anal 2011;54(3):445-450.
19. L'Homme RF, Muro EP, Droste JA, et al.: Therapeutic drug monitoring of nevirapine in resource-limited settings. Clin Infect Dis 2008;47(10):1339-1344.
20. Dubuisson JG, King JR, Stringer JS, Turner ML, Bennetto C, and Acosta EP: Detection of nevirapine in plasma using thinlayer chromatography. J Acquir Immune Defic Syndr 2004; 35(2):155-157.
21. Chi BH, Lee A, Acosta EP, Westerman LE, Sinkala M, and Stringer JS: Field performance of a thin-layer chromatography assay for detection of nevirapine in umbilical cord blood. HIV Clin Trials 2006;7(5):263-269.